This inventor holds 1 USPTO granted patent. Top assignee: Taiho Pharmaceuticals, Inc.. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Hiraku Itakdani: Innovator in Cancer Treatment
Introduction
Hiraku Itakdani is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on improving therapeutic efficacy for cancer patients using advanced methodologies.
Latest Patents
Hiraku Itakdani holds a patent for a method that predicts the therapeutic efficacy of PI3K/AKT/mTOR inhibitors based on the expression of PHLDA1 or PIK3C2B. This invention aims to provide a chemotherapy approach that produces excellent antitumor effects on cancer patients. The method utilizes the expression levels of specific biomarkers in biological samples containing tumor cells to assess the potential effectiveness of the treatment.
Career Highlights
Hiraku Itakdani is currently associated with Taiho Pharmaceuticals, Inc., where he continues to advance his research in oncology. His work is pivotal in developing targeted therapies that enhance patient outcomes in cancer treatment.
Collaborations
(Section skipped due to space constraints.)
Conclusion
Hiraku Itakdani's innovative approach to cancer treatment through his patented method exemplifies the potential of personalized medicine. His contributions are vital in the ongoing fight against cancer, aiming to improve the lives of patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile